Drug Profile
Zoliflodacin - Entasis Therapeutics
Alternative Names: AZD-0914; ETX-0914Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer Entasis Therapeutics; Global Antibiotic Research and Development Partnership
- Class Antibacterials; Ketones; Oxazines; Oxazolidinones; Pyrimidines; Quinolines; Spiro compounds
- Mechanism of Action DNA gyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gonorrhoea
Most Recent Events
- 29 Feb 2024 Innoviva announces intention to submit NDA to US FDA for Gonorrhoea in next twelve months
- 02 Nov 2023 Updated efficacy data from a phase III trial in Gonorrhea released by Innoviva
- 02 Aug 2023 Entasis Therapeutics completes enrolment in a phase III trial in Gonorrhoea (In adolescents, In adults, In the elderly) in USA, Belgium, Netherlands, South Africa and Thailand (PO) (NCT03959527)